Assessing the therapeutic potential of astaxanthin in experimental proliferative vitreoretinopathy models
European Journal of Ophthalmology · 2025
DOI: 10.1177/11206721251343166 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Ophthalmology, 2025. Verfasst von Hakan Veli Savaş und 6 weiteren Autor:innen. Beteiligte Einrichtung: Karakoçan State Hospital Eye Clinic, Elazığ, Turkey. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative, Disease Models, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Purpose
This study evaluates the effectiveness of astaxanthin in treating experimental proliferative vitreoretinopathy (PVR) in rats.
Methods
Fifty-six Sprague Dawley rats were divided into 4 groups. PVR was induced using dispase and astaxanthin was administered intravitreally at concentrations of 10 ng/μL and 100 ng/μL. The effects on TGF-ß, VEGF, PDGF, FGF2 and IL-1ß were measured by ELISA and retinal changes were analysed histopathologically and immunohistochemically.
Results
Astaxanthin at 10 ng/μL and 100 ng/μL administered to the treatment groups significantly decreased TGF-β, VEGF, FGF2, IL-1, and PDGF levels compared to the sham group ( p < 0.05). At the 100 ng/μL dose, more significant decreases were observed, especially in PDGF and IL-1 levels ( p < 0.01). Histopathologic scoring revealed that the treated groups had significantly lower PVR scores than the Sham group, with the highest dose showing the greatest improvement ( p < 0.01). Furthermore, treated groups exhibited improved retinal architecture and reduced fibrotic tissue formation. Immunohistochemical staining for VEGF was positive in all groups except Control, with no significant differences in VEGF expression intensity between groups.
Conclusion
Astaxanthin effectively reduces both biochemical and histopathological markers of PVR, highlighting its potential as a novel therapeutic agent for managing this challenging condition in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Karakoçan State Hospital Eye Clinic, Elazığ, Turkey.
- Fırat University Eye Clinic, Elazığ, Turkey.
- Fırat University, Elazığ, Turkey.
- Kayseri State Hospital Eye Clinic, Kayseri, Turkey.
ORCID-Profile: Hakan Veli Savaş, Hakan Yildirim, Nevin Ilhan, Yesari Eröksüz, Murat Erdağ, Mehmet Canleblebici, Mehmet Balbaba
Zitieren
APA
Savaş, H. V., Yildirim, H., Ilhan, N., Eröksüz, Y., Erdağ, M., Canleblebici, M., & Balbaba, M. (2025). Assessing the therapeutic potential of astaxanthin in experimental proliferative vitreoretinopathy models. European Journal of Ophthalmology. https://doi.org/10.1177/11206721251343166
Vancouver
Savaş HV, Yildirim H, Ilhan N, Eröksüz Y, Erdağ M, Canleblebici M, et al. Assessing the therapeutic potential of astaxanthin in experimental proliferative vitreoretinopathy models. European Journal of Ophthalmology. 2025. doi:10.1177/11206721251343166
BibTeX
@article{Sava2025,
author = {Savaş, Hakan Veli and Yildirim, Hakan and Ilhan, Nevin and Eröksüz, Yesari and Erdağ, Murat and Canleblebici, Mehmet and Balbaba, Mehmet},
title = {Assessing the therapeutic potential of astaxanthin in experimental proliferative vitreoretinopathy models},
journal = {European Journal of Ophthalmology},
year = {2025},
doi = {10.1177/11206721251343166}
}
EUVIMED